日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial

SURMOUNT-5试验结果显示，在肥胖或超重成人患者中，替泽帕肽与索玛鲁肽相比，可改善健康相关的生活质量。

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.70215
Shukla, Alpana P; Dunn, Julia P; Gomez Valderas, Elisa; Fraseur Brumm, Julia; Karanikas, Chrisanthi A; Hunter Gibble, Theresa
肥胖
代谢
发表日期：2026
文献求助 收藏

Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study

mirikizumab 对克罗恩病患者报告结局和生活质量的影响：来自 SERENITY II 期研究的结果

期刊:Crohns Colitis 360
影响因子:2.6
doi:10.1093/crocol/otag018
Jairath, Vipul; Hunter Gibble, Theresa; Peyrin-Biroulet, Laurent; Sands, Bruce E; Hirai, Fumihito; Hibi, Toshifumi; Loftus, Edward V Jr; Cross, Raymond K; Protic, Marijana; Chan, Lai Shan; Morris, Nathan; Traxler, Kristina; Rubin, David T
克罗恩病
发表日期：2026
文献求助 收藏

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment

接受替拉帕肽治疗后，身体机能评分最低的患者改善最为显著。

期刊:
影响因子:
doi:10.1002/oby.70067
Li, Xuan; Cao, Dachuang; Sapin, Helene; Wang, Fangyu; Hunter Gibble, Theresa; Raibulet, Nedina Kalezic; Denning, Max; Kaplan, Lee M
发表日期：2026
文献求助 收藏

Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database

在无 2 型糖尿病证据的个体中实际使用替泽帕肽：来自 Veradigm® 数据库的结果

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.16330
Hunter Gibble, Theresa; Chinthammit, Chanadda; Ward, Jennifer M; Cappell, Katherine; Sedgley, Robert; Bonafede, Machaon; Liao, Birong; Hankosky, Emily R
糖尿病
代谢
发表日期：2025
文献求助 收藏

Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study

在 2 期 AMAG 研究中，Mirikizumab 对中重度活动性克罗恩病患者的疲劳症状具有持续影响

期刊:Inflammatory Bowel Diseases
影响因子:4.3
doi:10.1093/ibd/izae166
Regueiro, Miguel; Fischer, Monika; Bossuyt, Peter; McGinnis, Kim; Protic, Marijana; Hunter Gibble, Theresa; Panni, Tommaso; Chan, Lai Shan; Hibi, Toshifumi; Rubin, David T
MAG
克罗恩病
发表日期：2025
文献求助 收藏

Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn's Disease: Results from the Japanese CONFIDE Study

患者和医护人员对溃疡性结肠炎和克罗恩病负担及日常生活影响的看法：来自日本 CONFIDE 研究的结果

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-03078-3
Hibi, Toshifumi; Kobayashi, Taku; Tanaka, Masaru; Osaga, Satoshi; Potts Bleakman, Alison J; Hunter Gibble, Theresa; Nedeljkovic Protic, Marijana; Redondo, Isabel; Matsuo, Koji; Hisamatsu, Tadakazu
结肠炎
克罗恩病
肠炎
IDE
发表日期：2025
文献求助 收藏

Exit Interviews Exploring Patients' Experience of Change in Crohn's Disease Symptoms During the Mirikizumab Phase 3 Clinical Trial In Adult Patients With Moderately-to-Severely Crohn's Disease

退出访谈：探索中重度克罗恩病成人患者在Mirikizumab 3期临床试验期间克罗恩病症状变化的体验

期刊:Crohns Colitis 360
影响因子:2.6
doi:10.1093/crocol/otae079
Hunter Gibble, Theresa; Macey, Jake; Makin, Harriet; Rosu, Rodica; Mellor, Katie; Kitchen, Helen; Hon, Emily; Dubinsky, Marla
克罗恩病
发表日期：2025
文献求助 收藏

Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial

替拉帕肽与肥胖或超重且患有 2 型糖尿病的成年人的健康相关生活质量改善相关：来自 3 期 SURMOUNT-2 试验的结果

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-025-01723-w
Hunter Gibble, Theresa; Cao, Dachuang; Zhang, Xiaotian Michelle; Xavier, Neena Agarwal; Poon, Jiat Ling; Fitch, Angela
糖尿病
肥胖
代谢
发表日期：2025
文献求助 收藏

Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme

在 LUCENT 3 期试验中，Mirikizumab 可早期且持续地控制溃疡性结肠炎患者的症状。

期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjae088
Danese, Silvio; Dignass, Axel; Matsuoka, Katsuyoshi; Ferrante, Marc; Long, Millie; Redondo, Isabel; Moses, Richard; Maier, Sebastian; Hunter Gibble, Theresa; Morris, Nathan; Milch, Catherine; Abreu, Maria T
结肠炎
肠炎
发表日期：2024
文献求助 收藏

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Mirikizumab 连续治疗溃疡性结肠炎 104 周后两年疗效和安全性：LUCENT-3 开放标签扩展研究结果

期刊:Inflammatory Bowel Diseases
影响因子:4.3
doi:10.1093/ibd/izae024
Sands, Bruce E; D'Haens, Geert; Clemow, David B; Irving, Peter M; Johns, Jordan T; Hunter Gibble, Theresa; Abreu, Maria T; Lee, Scott; Hisamatsu, Tadakazu; Kobayashi, Taku; Dubinsky, Marla C; Vermeire, Severine; Siegel, Corey A; Peyrin-Biroulet, Laurent; Moses, Richard E; Milata, Joe; Arora, Vipin; Panaccione, Remo; Dignass, Axel
NT-3
结肠炎
肠炎
发表日期：2024
文献求助 收藏